MEG3: A Non-Coding RNA Molecule as A Cancer Target Or Biomarker

Target Name: MEG3

NCBI ID: G55384

MEG3

Other Name(s): onco-lncRNA-83 | prebp1 | FLJ44703 | PRO2160 | maternally expressed 3 | MEG3 variant 1 | Prebp1 | NCRNA00023 | Maternally expressed 3, transcript variant 1 | FLJ31163 | LINC00023 | PRO0518 | FLJ42589 | FP504 | GTL2

MEG3: A Non-Coding RNA Molecule as A Cancer Target Or Biomarker

MEG3 (onco-lncRNA-83) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and several studies have investigated its potential role in disease progression.

MEG3 is a long non-coding RNA molecule that has a length of approximately 240 nucleotides. It is expressed in various tissues and cells throughout the body, including the brain, heart, and gastrointestinal tract. Its expression level varies depending on the cell type and the developmental stage of the organism.

One of the unique features of MEG3 is its expression pattern. It is predominantly expressed in the brain and heart, and its levels are highest in these regions. It is also expressed in the liver, pancreas, and gastrointestinal tract, but at much lower levels. This allows researchers to study its role in these specific tissues and organs, and to identify potential drug targets.

MEG3 has also been shown to play a role in several diseases, including cancer. Several studies have investigated its potential as a drug target or biomarker for cancer, and have shown that it is involved in the development and progression of several types of cancer, including neurobladder cancer, ovarian cancer, and prostate cancer.

One of the potential reasons for MEG3's involvement in cancer is its role in cell signaling. MEG3 has been shown to play a role in several signaling pathways that are involved in cancer development, including the PI3K/Akt signaling pathway and the TGF-β signaling pathway. These signaling pathways are involved in the regulation of cell growth, survival, and angiogenesis, and are often disrupted in cancer.

MEG3 has also been shown to interact with several other molecules that are involved in cancer development. For example, it has been shown to interact with the protein PDGF-BB, which is involved in the regulation of cell growth and survival. It has also been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation and cellular signaling.

Another potential reason for MEG3's involvement in cancer is its role in the regulation of gene expression. MEG3 has been shown to play a role in the regulation of the expression of several genes that are involved in cancer development, including the genes encoding the transcription factors p21 and p53. These genes are involved in the regulation of cell growth, apoptosis, and DNA damage repair, and are often disrupted in cancer.

In addition to its potential role in cancer, MEG3 has also been shown to have several potential therapeutic applications. For example, it has been shown to be involved in the regulation of pain perception, and has been shown to interact with the protein TrPV1, which is involved in the sensation of pain. This suggests that it may be a potential target for pain medications.

MEG3 has also been shown to be involved in the regulation of sleep-wake cycles, which is important for the regulation of circadian rhythms and the control of sleep-wake cycles. This suggests that it may be a potential target for interventions aimed at improving sleep quality and duration.

In conclusion, MEG3 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and several studies have shown that it is involved in the development and progression of cancer. Further research is needed to fully understand its role in disease progression and to identify potential therapeutic applications.

Protein Name: Maternally Expressed 3

The "MEG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets